Marrone bio innovations inc (MBII)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenues:
Total revenues

29,373

21,220

18,167

-

-

-

-

-

-

Product

-

-

-

13,715

8,976

7,750

7,588

6,777

5,044

License

-

-

-

327

333

232

193

179

57

Related party

-

-

-

0

492

1,154

665

184

150

Total revenues

-

-

-

14,042

9,801

9,136

8,446

7,140

5,251

Cost of product revenues

13,260

10,907

10,528

9,522

9,256

9,438

7,243

4,333

2,172

Gross profit

16,113

10,313

7,639

4,520

545

-302

1,203

2,807

3,079

Operating Expenses:
Research, development and patent

14,026

10,662

10,820

9,670

13,500

19,281

17,905

12,741

9,410

Non-cash charge associated with a convertible note

-

-

-

-

-

-

-

3,610

-

Selling, general and administrative

30,072

19,155

19,814

18,510

26,502

28,950

15,017

10,294

6,793

Total operating expenses

44,098

29,817

30,634

28,180

40,002

48,231

32,922

26,645

16,203

Loss from operations

-27,985

-19,504

-22,995

-23,660

-39,457

-48,533

-31,719

-23,838

-13,124

Other (expense) income:
Interest income

-

-

-

37

51

59

49

16

22

Interest expense

1,474

2,057

3,374

2,941

2,764

2,907

6,056

2,466

88

Interest expense, related parties

-

451

4,355

4,361

1,599

-

-

-

-

Change in fair value of financial instruments

-

-5,177

-96

-

-

-

-6,717

12,461

-1

Loss on extinguishment of debt, net

-

-2,196

-

-

-

-

49

0

-

Gain on extinguishment of debt, related party

-

9,183

-

-

-

-

-

-

-

Loss on modification of warrants

-1,564

-

-

-

-

-

-

-

-

Loss on issuance of new warrants

6,065

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-342

-

-

-

-

-

-

-

-

Change in estimated fair value of derivative liability

-

-

-

0

0

-

-

-

-

Other income, net

255

-11

-105

-146

41

-278

-282

-45

9

Total other (expense) income, net

-9,190

-709

-7,930

-7,411

-4,271

-3,126

477

-14,956

-56

Loss before taxes

-

-

-

-31,071

-43,728

-51,659

-31,242

-38,794

-

Loss before income taxes

-

-

-

-

-

-

-

-

-13,180

Income tax expense

-

-

-

0

0

0

0

0

0

Net loss

-37,175

-20,213

-30,925

-31,071

-43,728

-51,659

-31,242

-38,794

-

Basic and diluted net loss per common share:

-0.32

-0.20

-1.06

-1.26

-1.79

-2.32

-

-

-

Weighted-average shares outstanding used in computing basic and diluted net loss per common share:

117,982

101,248

29,235

24,617

24,469

22,314

-

-

-

Net loss

-

-

-

-

-

-

-

-

-13,180

Deemed dividend on convertible notes

-

-

-

-

-

-

1,378

2,039

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-32,620

-40,833

-13,180

Basic

-

-

-

-

-

-

-3.74

-32.48

-10.64

Diluted

-

-

-

-

-

-

-4.25

-32.48

-10.64

Basic

-

-

-

-

-

-

8,731

1,257

1,239

Diluted

-

-

-

-

-

-

8,911

1,257

1,239

Product [Member]
Total revenues

28,912

20,775

17,935

-

-

-

-

-

-

License [Member]
Total revenues

461

445

232

-

-

-

-

-

-